Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Below 50-Day Moving Average of $1.03

Seres Therapeutics, Inc. (NASDAQ:MCRB) passed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $1.03 and traded as low as $0.75. Seres Therapeutics shares last traded at $0.78, with a volume of 3,298,905 shares trading hands.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on MCRB. Chardan Capital decreased their target price on Seres Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, March 6th. Oppenheimer decreased their target price on Seres Therapeutics from $9.00 to $5.00 and set an “outperform” rating on the stock in a report on Wednesday, March 6th.

Seres Therapeutics Price Performance

The company has a current ratio of 1.78, a quick ratio of 1.48 and a debt-to-equity ratio of 4.45. The firm has a market cap of $117.82 million, a PE ratio of -0.87 and a beta of 2.29. The stock has a 50 day simple moving average of $1.03 and a 200-day simple moving average of $1.36.

Institutional Investors Weigh In On Seres Therapeutics

Institutional investors have recently bought and sold shares of the business. State Street Corp grew its position in shares of Seres Therapeutics by 127.3% during the second quarter. State Street Corp now owns 8,564,935 shares of the biotechnology company’s stock valued at $41,026,000 after purchasing an additional 4,796,626 shares in the last quarter. Federated Hermes Inc. grew its position in shares of Seres Therapeutics by 15.9% during the first quarter. Federated Hermes Inc. now owns 8,010,806 shares of the biotechnology company’s stock valued at $57,037,000 after purchasing an additional 1,096,670 shares in the last quarter. BlackRock Inc. grew its position in shares of Seres Therapeutics by 19.7% during the second quarter. BlackRock Inc. now owns 7,481,227 shares of the biotechnology company’s stock valued at $35,835,000 after purchasing an additional 1,232,141 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Seres Therapeutics by 24.0% during the third quarter. Vanguard Group Inc. now owns 6,610,856 shares of the biotechnology company’s stock valued at $42,442,000 after purchasing an additional 1,280,039 shares in the last quarter. Hedge funds and other institutional investors own 59.34% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.